Positively Positive – Living with HIV/AIDS:
HIV/AIDS News
HIV, AIDS and Infectious Disease News
from around the world
Worldwide 91.4 million people have been infected with HIV.
Worldwide 44.1 million people with HIV have died.
Worldwide, 40.8 million people were living with HIV at the end of 2024.
.
Practicing Safe Sex is our best resource in preventing HIV infection through sexual contact.
Sexual contact accounts for 95 percent of all new HIV infections worldwide.
Safe Sex = Disease Prevention – STAY SAFE!
Use A Condom Every Time!
“HIV needs to be in the media each and every day as most people only see snippets of news and these are not effective enough. For this reason, in 2007, I decided to include an HIV/AIDS News page where people could find information on many HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) related issues, Infectious Disease,
and more.
I collaborate with individuals, groups, and organizations throughout the world, to include their HIV/AIDS news articles, press releases, events, workshops, conferences, and more on PositivelyPositive.ca. News items stay on the HIV/AIDS News page for a month,
and then News items go into the HIV/AIDS News Archives.”
Bradford McIntyre
Positively Positive Marks 23 Years Online: Creating Global HIV/AIDS Awareness
August 15, 2026 - Celebrating 23 years of www.PositivelyPositive.ca. Long-term HIV survivor Bradford McIntyre shares a historic reflection dedicated to creating HIV/AIDS awareness, fighting stigma, and showcasing the global efforts working to end HIV and AIDS
August 15, 2026, marks the 23rd anniversary of the launch of my website: “Bradford McIntyre Positively Positive Living with HIV/AIDS” (www.PositivelyPositive.ca). Designed to create awareness around the many HIV and AIDS issues and promote messages of positive living with HIV, the website has grown from a modest 20-page site in 2003 into an internationally recognized information and resource hub. To date, this independent, ad-free website has reached 21,494,155 hits from 187 countries globally.
As the founder and operator living openly with the HIV virus since 1984. In 1994, he entered public advocacy by appearing on national television to combat the heavy burden of HIV stigma and discrimination. Nearly a decade later, he launched his website to create a visible face for the movement and provide global connection.
Long-acting therapies continue to gain momentum in HIV, says GlobalData
11 August 2026 - GlobalData - The next phase of competition in the HIV market will be defined not only by achieving viral suppression, but by improving treatment adherence, reducing medication burden and delivering more convenient treatment options, with long-acting therapies at the forefront, according to GlobalData, a leading intelligence and productivity platform.
GlobalData forecasts that the HIV market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) will grow from $26.4 billion in 2023 to $30.6 billion by 2033, with increased uptake of long-acting therapies representing a key driver of growth.
Findings presented at the 26th International AIDS Conference (AIDS 2026) included positive new data for ViiV Healthcare’s Cabenuva (cabotegravir/rilpivirine) among adolescents living with HIV.
Canada falling behind on funding HIV care as infections rise: experts
August 10, 2026 - CityNews - Advocates are calling on the federal government to do more as HIV infections in Canada see its largest increase in a two-year period. Sean Hosein, Science and Medicine Editor at Canadian AIDS Treatment Information Exchange explains.
watch Video...
Sharon Stone and John Stamos to Be Honored at the Creative Coalition’s Humanitarian Awards (EXCLUSIVE)
August 10, 2026 - By Matt Minton - Variety - Additional honorees at the pre-Emmys event include Simran Baidwan, Cara Buono, Lisa Ann Walter and Mary Lou Belli.
Sharon Stone and John Stamos are set to be honored at The Creative Coalition’s Humanitarian Awards.
Read more...
‘We are living in reverse.’ Fragile HIV funding puts another strain on Kansas City’s safety net
August 10, 2026 - By Suzanne King - The Beacon - HIV health providers have already absorbed some cuts and fear more. They worry that gains made toward eliminating the virus are in jeopardy.
Roberto Archuleta was 21 years old in 1991 when he found out he was HIV-positive.
At the time, the only medications available to treat the virus were difficult to tolerate and often ineffective. Being diagnosed was commonly a death sentence — something Archuleta, then a hairstylist in Kansas City, witnessed too often.
Read more...
The Last Mile of Care: Community Health Workers in Lesotho
AUGUST 8, 2026 -The Borgen Project - For residents of Lesotho’s mountain districts, reaching a clinic means a walk of several hours across some parts of southern Africa’s highest terrain. This distance determines who receives treatment just as much as a shortage of treatment. Yet a growing network of community health workers in Lesotho is narrowing that gap, carrying Human Immunodeficiency Syndrome (HIV) treatment support, maternal care and disease monitoring directly into villages that the formal health system has struggled to reach.
A Health System Under Strain
Lesotho carries one of the heaviest HIV burdens in the world. An estimated 18.5% of adults ages 15 to 49 were living with HIV in 2023, and roughly 236,000 people 15 and older were on antiretroviral therapy that year, according to the U.S. Centers for Disease Control and Prevention (CDC). Tuberculosis compounds the crisis: an estimated 664 cases occurred per 100,000 people in 2023, and half of all Tuberculosis (TB) cases involved HIV coinfection, making continuous, coordinated care essential rather than optional.
Cutbacks in global aid could spark HIV epidemic resurgence
August 7, 2026 - By Heather Klein - THE WINNIPEG SUN - A new class of drugs called CD4 mimetics could be used to sensitise the immune system to HIV, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard last week.
It is becoming clear that broadly neutralising antibodies, whether infused as a drug or generated by a vaccine, may not be sufficient to cure HIV, or even to lead to long-term remission off antiretroviral therapy.
Read more...
Tumor-like tissue environments could hold clues to curing HIV
August 7, 2026 - Northwestern Now - Northwestern University - - Study microenvironment in animal models -
- Comparisons between virus and tumor microenvironment -
- Used novel molecular imaging and spatial transcriptomics -
The tissue microenvironments surrounding HIV-infected immune cells look a lot like those surrounding cancerous tumors, reports a new Northwestern University study.
The findings help explain why HIV has been so difficult to cure. Scientists found that viral reservoirs exist within tissue microenvironments that resemble immune-suppressive tumor microenvironments, suggesting that future HIV cure strategies may benefit from approaches traditionally used in cancer therapy.
The study was published Aug. 4 in the journal Frontiers in Immunology.
What China’s expanded funding for HIV/Aids in Africa means as US cuts health aid
7 August 2026 - By Jevans Nyabiage - South China Morning Post - Beijing backs local medicine manufacturing, with senior UN official voicing gratitude for ‘strong commitment to multilateralism’
China is expanding its role in the fight against HIV/Aids in Africa by funding new projects and backing local medicine manufacturing as part of its signature health initiative, the Health Silk Road.
Read more...
A new class of drugs could sharpen the body’s immune response to HIV
7 August 2026 - By Gus Cairns - The News Pakistan - Two Alberta infectious disease specialists have launched a national coalition aimed at preventing a resurgence of HIV infections as international funding cuts threaten decades of progress against the virus.
Dr. M. John Gill and Dr. Raynell Lang, both with the University of Calgary, have formed the Canadian Strategic Consortium to Address the Changing Policies and Environment of Global HIV Care, known as CanSCAPE-HIV.
Read more...
Returning to HIV care does not erase the effects of treatment interruption, studies show
6 August 2026 - By Edith Magak - aidsmap - CD4 counts fall much faster than they recover, increasing the harms of cycling in and out of care
People with HIV in South Africa are ten times more likely to develop tuberculosis while interrupting treatment than while taking it, the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro heard last week. Even after resuming treatment and achieving viral suppression, their risk stayed 50% higher.
Read more...
‘25,000 HIV/Aids deaths recorded since first case in 1987’
Islamabad: August 06, 2026 - By M. Waqar Bhatti - The News Pakistan - More than 25,000 peop1le, including hundreds of children, have officially died of HIV infection and Aids-related illnesses in Pakistan since the country’s first Aids case was reported in Lahore in 1987, data compiled by the federal and provincial health departments reveal.
Read more...
Gareth Thomas opens up on life with HIV after admitting husband is shunned
05 Aug 2026 - By Maria Ortega and Tom Sunderland - Wales Online - Welsh sporting icon Gareth Thomas has found new ways to savour his life despite his HIV diagnosis. However, the former Cardiff and Toulouse star has commented in the past about how the condition has resulted in repercussions for his loved ones.
Read more...
Russia Says Its HIV Rates Are Falling. Experts Aren’t So Sure.
August 5, 2026 - By Maria Ortega and Tom Sunderland - The Moscow Times - Four years ago, while hospitalized with Covid-19, St. Petersburg singer Ksenia Aleksandrova was unexpectedly diagnosed with HIV.
Known by her stage name Neksusha, the 23-year-old Aleksandrova has built a devoted online following, with around 90,000 subscribers on YouTube and more than 213,000 monthly listeners on Spotify. Despite the persistent stigma that surrounds HIV, she decided to publicly disclose her diagnosis in an effort to raise awareness about the illness.
Read more...
Once-weekly HIV therapy may offer alternative to daily pills
August 4, 2026 - By Laine Bergeson - CIDRAP - Center for Infectious Disease Research & Policy - University of Minnesota - A once-weekly oral HIV treatment maintained viral suppression as effectively as a standard once-daily regimen in a phase 3 clinical trial, offering a potential new treatment option for people living with HIV.
The randomized, double-blind trial, published in the New England Journal of Medicine last week, looked at a once-weekly combination tablet containing islatravir and lenacapavir in adults whose HIV had remained suppressed for at least six months while taking the daily regimen bictegravir–emtricitabine–tenofovir alafenamide.
Enhanced access to diagnostic screening improves care for advanced HIV
4 August 2026 - By Keith Alcorn - aidsmap - Two studies presented at the 26th International AIDS Conference (AIDS 2026) last week show that wider access to diagnostic testing and consistent implementation of screening guidance could each improve the diagnosis of opportunistic infections in people with low CD4 counts.
World Health Organization (WHO) guidance recommends that all people with HIV should receive a CD4 cell test at diagnosis or when re-engaging with care after a treatment gap.
Read more...
New HIV infections in Canada are rising. Advocates say years of progress are at risk
Aug 01, 2026 - By Tashauna Reid - CBC - New HIV infections increased by 23% in 2024, Public Health Agency of Canada says
Dr. Julio Montaner has spent decades in the fight against HIV but says he feels years of progress slipping away.
“I am very worried about what’s coming our way,” said Montaner, executive director and physician-in-chief at the BC Centre for Excellence in HIV/AIDS in Vancouver, the largest HIV/AIDS research and treatment facility in Canada.
Listen & Read more...
Risk of death 21% lower in people with HIV-related fungal disease given combination drug treatment
31 July 2026 - City St George’s, University of London - In a clinical trial of adults with HIV-related cryptococcal disease, those treated with a two-drug combination had a 21% lower risk of dying than those treated with just one drug. This is according to City St George’s research being presented today at the International AIDS Conference 2026 in Brazil
Meningitis caused by the Cryptococcus fungus is an infection of the membranes covering the brain and spinal cord, as well as the brain itself. The destructive condition is responsible for around 110,000 deaths globally every year and accounts for almost 20% of HIV-related deaths. People with this type of meningitis often only have a short window left to live, with between a third to a half dying within 10 weeks even with treatment – a death rate similar to the Bundibugyo strain of Ebola virus disease.
amfAR Senior Policy Associate Elise Lankiewicz Awarded Journal of the International AIDS Society’s Impact Award
RIO DE JANEIRO, July 31, 2026 - amfAR, The Foundation for AIDS Research - The award, selected by the journal’s Editorial Board members and Deputy Editors, acknowledges high-impact publications from the previous year
Elise Lankiewicz, amfAR Senior Policy Associate, accepted the Impact Award from the Journal of the International AIDS Society presented on the final day of the 2026 International AIDS Conference. The Impact Award recognizes high-impact publications from the International AIDS Society’s journal; Lankiewicz and co-lead author Alana Sharp won for a February 2025 publication: “Early impacts of the PEPFAR stop-work order: a rapid assessment.”
Trump to HIV and Cancer Patients: Get Back to Work
July 31, 2026 - By David Dayen - THE AMERICAN PROSPECT - A surprise rule added to the Big Beautiful Bill could disrupt access to Medicaid for people with serious illnesses who thought they were exempted from work requirements.
Yesterday was the 61st anniversary of the signing of Medicare and Medicaid, a promise by the government to at least care for the oldest and most vulnerable people in our society. Today is the deadline for public comment on a rule that could force severely ill patients with cancer, HIV, and other ailments to get out of their hospital beds and go to work if they want the government to keep that promise.
Listen to this article...
HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts
31 Jul 2026 - By Hannah Harris Green in Rio de Janeiro - The Guardian - Injectable PrEP drug holds promise but investment in HIV prevention has declined dramatically worldwide
New innovations in HIV prevention could dramatically reduce the number of new HIV cases around the globe, but US foreign aid cuts will mean that those that most need the new medication will be unable to access it, according to experts at the Aids 2026 Conference in Rio de Janeiro, Brazil.
Read more...
HIV infections on the rise in Canada despite global decrease
July 30, 2026 - By Tiffany Crawford - Vancouver Sun - Canada has all the tools it needs to end the HIV epidemic but the country is failing to do so because of a lack of funding, say experts.
The number of HIV infections has increased in Canada despite a global decrease but experts say the country has the resources to wipe out the world epidemic.
Read more...
Protecting Californians from HIV
July 30, 2026 - University of California, Berkeley - Dr. Stef Bertozzi and Dr. Lauren Hunter outline path to more patients receiving lifesaving HIV prevention medications
As the top public university in the United States, UC Berkeley sets the bar when it comes to research innovations that transform how we live, think, and thrive.
At UC Berkeley Public Health, our rigorous health research translates into strategies that improve population health in our state, our nation, and around the world.
TAF (Vemlidy) now listed for hepatitis B virus treatment on provincial and federal formularies in Canada
July 30, 2026 - Canadian AIDS Treatment Information Exchange (CATIE) - Tenofovir alafenamide (TAF) is recommended for treating hepatitis B
However, many people do not have private insurance and cannot afford the drug
Provinces across Canada recently agreed to subsidize TAF for people with hepatitis B
Rates of new hepatitis B virus (HBV) infections continue to increase in Canada. There are approximately 262,000 people living with chronic HBV in Canada—and scientists estimate that nearly 50% of these people are not aware that they have HBV. If left undiagnosed and untreated, chronic HBV can cause serious complications, including liver cancer. HBV infection is spread through similar routes as hepatitis C virus (HCV) and HIV. HBV can be detected with blood tests and treatment is available. There is also a vaccine that can help to prevent HBV infection.
Failing to tackle inequality puts countries in pandemic danger, new research shows
July 30, 2026 - UNAIDS - Call for “Inequality-Informed Pandemic Preparedness and Response”
Analysis in the New England Journal of Medicine – co-authored by experts including Nobel laureate Joseph Stiglitz, leading epidemiologist Professor Sir Michael Marmot, and Chairperson of the One Economy Foundation and former First Lady of Namibia Monica Geingos – finds economic inequality, not conventional preparedness, has been the clearest predictor of how countries fared against pandemics, upending traditional assumptions about what actions governments need to take for health security. The new research from the Global Council on Inequality, AIDS and Pandemics finds that while technical capacity remains necessary, it is not sufficient. To respond to and prepare for pandemics effectively, governments need to include efforts to address inequality.
Once-weekly islatravir / lenacapavir combination pill maintains HIV viral suppression
30 July 2026 - By Liz Highleyman - aidsmap - A once-weekly single-tablet regimen containing islatravir and lenacapavir maintained viral suppression in people with HIV who switched from standard daily oral treatment, according to a pair of studies presented yesterday at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro.
Read more...
AIDS Walk San Francisco 2026 Raises Over $815,000 So Far
July 30, 2026 - San Francisco Bay Times - AIDS Walk San Francisco 2026, held on July 19 in Golden Gate Park, marked 40 years of community action in the fight against HIV/AIDS, continuing its legacy as one of Northern California’s largest and most visible fundraising events. Building on decades of grassroots momentum that has raised more than $100 million overall for Bay Area organizations, the annual event this year has raised over $815,000 so far.
Read more...
U.S. says ‘error’ mislabelled every African country on AIDS conference map
July 30, 2026 - By Sean Boynton - Global News - The U.S. government on Thursday acknowledged an “unfortunate error” that led to a map of Africa with every single country mislabelled being shown at a global AIDS conference this week.
The mislabelled map was shown during a presentation at the AIDS 2026 Conference in Rio de Janeiro on the U.S. State Department’s new health program funding agreements with African nations, which are being reworked after the Trump administration reduced global aid last year.
Read more...
As sustained heatwaves increase the risk of infectious diseases across Europe, ECDC scales up action and calls for cooperation
Stockholm, 29 July, 2026 - European Centre for Disease Prevention (ECDC) - The risk of catching some infectious diseases is growing amidst longer, warmer summers across Europe, making close cooperation across borders and specialisations vital to predict, prevent, and respond effectively, the European Centre for Disease Prevention and Control (ECDC) said today.
While the current heatwaves are making headlines, it is the continuously higher temperatures of an ever longer duration that create the conditions for many infections to spread. This summer, ECDC’s ongoing monitoring and data collection highlights four areas of particular urgency:
World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach
Stockholm, 28 July 20266 - European Centre for Disease Prevention (ECDC) - While Europe has made steady progress in preventing hepatitis B and C, with the prevalence of hepatitis B now at near-zero levels among children below five years old, an uneven implementation of key measures means that the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat, according to new data from the European Centre for Disease Prevention and Control (ECDC) on World Hepatitis Day.
‘No one should die from a disease that is preventable, diagnosable and treatable,’ says Bruno Ciancio of ECDC. ‘Yet millions of Europeans are living with chronic hepatitis B or C infections – often without knowing it – which can lead to severe long-term consequences such as liver failure or liver cancer. World Hepatitis Day is a good opportunity to remember that effective solutions to control viral hepatitis already exist. Our collective challenge is to ensure that these life-saving interventions are accessible to everyone who needs them.’
New report reveals consequences of Trump administration's HIV/AIDS funding cuts
Jul 28, 2026 - PBS NEWS HOUR - A new report is detailing the impact of cuts to USAID and the program known as PEPFAR, which has been credited with saving over 26 million lives since 2003. The study from the HIV/AIDS non-profit amfAR found that more than 1,700 treatment sites have closed in the wake of funding cuts. William Brangham discussed more with Dr. Atul Gawande, the assistant administrator of USAID under President Biden.
Watch Video...
Health Matters: Early screening will help protect your from hepatitis B
July 28, 2026 - GLOBAL NEWS - A new survey suggests most Canadians know very little about hepatitis B, even though it can lead to serious liver disease. Dr. Alnoor Ramji, a hepatologist at Providence Health Care, explains why awareness and screening matter.
Watch Video...
Canada sees a 23 per cent rise in HIV cases since 2022
July 28, 2026 - CTV News - Jody Jollimore, executive director of Canadian AIDS Treatment Information Exchange, speaks about why Canada's HIV infection rate has been increasing.
Watch Video...
Can We Teach the Immune System to Control HIV on Its Own?
Jul 29, 2026 - By Andy Carstens - TheBody - Most people’s immune systems can’t effectively fight HIV. But a few can: These people, dubbed “elite controllers,” can maintain an undetectable viral load over a long period of time with no antiretroviral therapy (ART). Though many eventually do see their viral load rise, some retain the ability to control HIV for years or even decades.
Watch Video...
In memoriam: Dr. Roger Detels, HIV/AIDS researcher and public health leader
July 27, 2026 - By Carla Denly - UCLA - Dr. Roger Detels, former dean and distinguished professor of epidemiology in the UCLA Fielding School of Public Health, died July 25.
Over the course of his illustrious career, which included 56 years of service to the school, Detels conducted research on air pollution, multiple sclerosis and other neurologic diseases, hypertension and several infectious diseases, including trachoma, capillariasis and Japanese encephalitis. Yet he is perhaps best known for his research on HIV/AIDS, which he began in 1981 when he initiated a natural history study of AIDS in young homosexual men in Los Angeles.
Lancet Report Recommends Paradigm Shift in Care for Older Adults with HIV
Newswise - 27-Jul-2026 - by Johns Hopkins Bloomberg School of Public Health - Expanding care beyond essential antiviral therapy will help support growing older population with HIV expected to reach 20.2 million worldwide by 2040
A new report by a group of HIV researchers in the journal Lancet HIV recommends that health systems caring for older individuals with HIV should move beyond the standard antiretroviral therapy to a more comprehensive, healthy-aging approach. The report was led by researchers at the Johns Hopkins Bloomberg School of Public Health and Yale School of Medicine, with colleagues at more than 40 institutions and nine persons living with HIV.
While most new HIV cases are among young people, the number of individuals living with HIV worldwide is increasing and getting older: nearly a third of people with HIV were over 50 in 2025, and half will be over 50 by the year 2040. In their report, commissioned by the editors of the journal Lancet HIV, the authors recommend a broad set of health-system changes to manage the distinct challenges involved in HIV prevention and screening, treatment, and long-term care in this older population.
Global HIV response falters as reemergence looms
RIO DE JANEIRO/GENEVA, 27 July 2026 - UNAIDS - In 2025, 1.2 million more people became infected with HIV and 570 000 more people died of AIDS-related illnesses as the world fell short of global targets. Without urgent action to meet the 2030 goals, more than 3 million could become infected with HIV by 2030.
A special report released by UNAIDS for the 26th International AIDS Conference taking place in Rio de Janeiro, Brazil from 27 to 31 July, shows that reductions to international funding and cuts to HIV prevention and community services are likely to lead to a resurgence of the epidemic.
Although new HIV infections and AIDS-related deaths are at their lowest levels in more than 30 years, the current HIV response is extremely fragile. Efforts to end AIDS as a public health threat by 2030 are at risk unless global solidarity is restored and inequalities are addressed.
In 2025, 1.2 million people acquired HIV, but progress is uneven. New HIV infections rose in three regions and 21 countries in 2025. Around 9 million of the 41 million people living with HIV were not on treatment and almost half of all children living with HIV did not have access to antiretroviral therapy in 2025. More than half a million people (570 000) died of AIDS-related illnesses in 2025.
 
Funding for the global HIV response plunged in 2025, with devastating consequences
27 July 2026 (Rio de Janeiro, Brazil) – AIDS 2026 - IAS - International AIDS Society - Declines in US disbursements drove an unprecedented 25% drop in funding from donor governments, putting decades of progress at risk
Funding for the global HIV response plunged in 2025 – entirely due to a steep decline in US support – putting decades of progress at risk, according to reports from UNAIDS and KFF released at AIDS 2026, the 26th International AIDS Conference.
Convened by IAS – the International AIDS Society – AIDS 2026 opened in Rio de Janeiro, Brazil, bringing together approximately 7,000 scientists, policy makers, healthcare providers, funders and people living with and affected by HIV from around the world.
At a press briefing ahead of the opening session, global health leaders called on donor governments to sustain robust support for the HIV response, and on low- and middle-income countries to continue stepping up their own investments where possible.
“We come to Rio de Janeiro at a moment of real danger for the HIV response,” Beatriz Grinsztejn, IAS President and AIDS 2026 International Co-Chair, said. “Never has donor funding fallen so far, so fast, and those most vulnerable are already paying the price. Donor countries are choosing to walk away while many high-burden countries remain shackled by debt they cannot escape. We must rethink outdated models, rebuild what has been broken, and rise to ensure the response gets the resources it needs.”
Media briefing featuring Brazil’s Minister of Health, the Director of PAHO and the Director-General of WHO
27 July 2026 (Rio de Janeiro, Brazil) – AIDS 2026 - IAS - International AIDS Society -
Date: Monday, 27 July 2026
Time: 16:00–16:30 BRT
Location: Press conference room (Room 211), Riocentro Convention & Event Center, Rio de Janeiro, Brazil
Link to register for virtual participation
The on-the-record briefing will provide an opportunity for media to hear directly from three global health leaders and to pose direct questions.
Mitchell Warren on the fallout from PEPFAR cuts | AIDS 2026
July 26, 2026 - Managed Healthcare Executive - People are beginning to fall out of treatment because of the PEPFAR funding cuts but the infrastructure of the programs has survived, says the executive director off AVAC, a U.S. organization that advocates for HIV prevention.
New survey data released ahead of AIDS 2026 meeting in Rio de Janeiro, Brazil, provided some clues about what the disruption in the funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has meant for PEPFAR-funded programs. According to a survey of PEPFAR-funded organizations conducted by amfAR, The Foundation for AIDS Research, 1,700 HIV/AIDS service sites have closed. Other research found that approximately 77,000 fewer children living with HIV received PEPFAR-supported treatment in 2025 than in 2024
Watch Video...
The ‘cruel irony’ of great science, terrible politics and economics in HIV/AIDS treatment and prevention | AIDS 2026
July 26, 2026 - Managed Healthcare Executive - AVAC Executive Director Mitchell Warren says HIV prevention science has never been stronger, even as funding cuts have left program infrastructure badly weakened.
HIV prevention science has never been stronger, but the funding and infrastructure needed to deliver it have been badly weakened, according to Mitchell Warren, executive director of AVAC, a U.S.-based organization that advocates for HIV prevention. Warren spoke with Managed Healthcare Executive ahead of the AIDS 2026, the 26th International AIDS Conference, a meeting sponsored by the International AIDS Society ((IAS), which opens Monday in Rio de Janeiro, Brazil.
Watch Video...
Mitchell Warren on weekly islatravir-lenacapavir for HIV treatment | AIDS 2026
July 26, 2026 - Managed Healthcare Executive - A once-weekly oral HIV treatment could make a major difference in resource-constrained settings, says the executive director of AVAC.
Positive results from two phase 3 trials, ISLEND-1 and ISLEND-2, testing a once-weekly combination pill are looking to be one of the standout findings presented at AIDS 2026, the 26th International AIDS Conference in Rio de Janeiro, Brazil. The once-weekly combination pairs oral lenacapavir, from Gilead Sciences, with islatravir, from Merck — a partnership between two companies that are typically competitors in HIV therapeutics. Researchers reported the results at a press conference last week in advance of the AIDS 2026 meeting that is scheduled to start tomorrow.
Watch Video...
Activists Disrupt U.S. Global AIDS Coordinator Jeff Graham at International AIDS Conference, Protesting Trump’s Chokehold on Congressionally Appropriated HIV Funding, Mass Closure of Key Population Programs, and Attacks on Transparent Oversight of PEPFAR Programs
(Rio de Janeiro) – July 26, 2026 - Health GAP - New Data Show Trump and Rubio Responsible for Severe Deterioration in Program Outcomes, Including HIV Treatment Cut for 77,163 Children, 42% Reduction in PrEP Enrollment, Closure of 1700 PEPFAR HIV Treatment Sites, and More
“The U.S. government must be held accountable for the ongoing, global public health emergency they are causing,” said Anele Yawa of South Africa’s Treatment Action Campaign. “No matter what the U.S. says in conference halls, we must believe the people served by PEPFAR, believe the data, and demand the U.S. reverse course.”
“Erasing decades of progress and accountability to people with HIV and key populations is an outrage, and we must not allow it to continue on our watch,” said Asia Russell of Health GAP.
Forty-Five Years Of HIV/AIDS And We’re Still Ignoring Black Women’s Leadership, Says New Book, Ill Erotics
July 26, 2026 - ByJallicia Jolly - Forbes - Forty-five years after the first AIDS case, scientific breakthroughs like ART and PrEP have transformed HIV into a manageable condition, yet the pandemic is far from over. Governments are retreating from public health commitments, leading to unequal distribution of care. Racial and sexual minorities, particularly Black women, continue to face disproportionate burdens due to structural inequities. Despite this, Black women have been crucial, innovative leaders, advocates, and architects of community-based care, building essential support systems when institutions failed. Their work, exemplified by figures like Katrina Haslip and organizations like EVE for Life, highlights that sustained community infrastructure, not just medicine, is vital for health. This leadership offers critical lessons for future public health, emphasizing that care is an intentional investment, not charity, and requires continuous support beyond headlines.
Read more...
Window of Knowledge HIV/AIDS gathers scientific evidence
São Paulo, July 24, 2026 (BIREME/PAHO/WHO) - Pan American Health Organization | PAHO - From July 26 to 30, Brazil will host the 26th International AIDS Conference (AIDS 2026), the world's leading conference dedicated to the global HIV response. Held in Rio de Janeiro, the event will bring together people living with HIV, researchers, health professionals, public health leaders, policymakers, civil society representatives, international organizations, and funders to discuss the challenges and priorities of the global response to the epidemic.
Under the theme “Rethink. Rebuild. Rise.”, the conference takes place at a time of significant challenges to the sustainability of HIV programs, including the need to strengthen national responses based on evidence, innovation, equity, and international cooperation.
New Drug Could Contribute to Stopping Measles Outbreaks
ATLANTA – July 24, 2026 - Georgia State University - A new oral antiviral drug candidate administered either before or after direct contact or airborne exposure to canine distemper virus, which causes measles-like disease in ferrets, blocks transmission of the virus and reduces clinical symptoms, according to a study published in the journal Nature Microbiology by researchers in the Center for Translational Antiviral Research (CTAR) at Georgia State University.
The study explored whether prophylactic (shortly before or after exposure) administration of the recently developed clinical candidate GHP-88310 (described in Science Advances), a broad-spectrum inhibitor of the viral polymerase, prevents virus transmission through close contact or through the air. The results demonstrate that GHP-88310 efficiently blocks both forms of viral spread. In addition, the study showed that treatment of infected animals shortened the time period in which infected animals could transmit the virus.
AVAC and Access Bridge Applaud Monthly PrEP Pill Access Announcement; Call for Speed, Scale and Equity in Future Monthly Oral Alimatravir Introduction
Rio de Janeiro, Brazil, 24 July 2026 - AVAC - AVAC and Access Bridge applaud Merck’s announcement today that it has granted seven direct licenses to generic manufacturers to produce their investigational monthly pill for HIV prevention, known as MK-8527, or alimatravir, while Phase 3 clilnica trials are still enrolling.
The announcement from Merck/MSD reflects responsiveness to advocates’ longstanding calls to accelerate access to PrEP options. Since 2012, each successive PrEP introduction has gone faster than the previous one, yet the time to market and to public health impact remains too slow.
In advance of the AIDS 2026 conference, Merck, known as MSD outside the US and Canada, today announced voluntary licensing agreements with seven manufacturers, including three in East and Southern Africa, to produce and market alimatravir for PrEP in 129 countries.
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
RAHWAY, N.J.--(BUSINESS WIRE) - June 24, 2026 - Merck & Co., Inc. - - Multi-faceted strategy aims to enable rapid, broad and sustainable access to alimatravir (MK-8527), if approved, in low- and middle-income countries -
- Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally -
- As Phase 3 trials continue, Merck is committed to advancing access plans, working in close collaboration with the HIV community and global health stakeholders -
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries (LMICs) to alimatravir (MK-8527), an investigational, novel, once-monthly oral pill as pre-exposure prophylaxis (PrEP) for the prevention of HIV-1, following regulatory approval. Initial access plans as part of Merck’s broader strategy include establishing early generic licensing covering 129 LMICs; supporting targeted, regional manufacturing capabilities in Africa and Latin America; and investing early in product manufacturing to enable timely access and availability in regions of high unmet need. The first steps of this strategy are being announced in the lead up to the 26th International AIDS Conference in Rio de Janeiro, Brazil.
UNAIDS at the 26th International AIDS conference
July 24, 2026 - UNAIDS - AIDS 2026 will be the first major global gathering following the UN General Assembly High-Level Meeting on HIV and AIDS where countries came together and committed to new targets as part of efforts to end AIDS as a public health threat by 2030.
The conference comes at a critical moment as these global commitments must translate into country-level implementation. Sustained political leadership is needed as well as and concrete financing commitments from both donors and countries most affected by HIV, particularly in a time of constrained resources.
On the opening day of the conference (27 July), UNAIDS will be releasing a special report, United to End AIDS, which gives the latest data on HIV from 2025.
Fact Sheet: U.S. Government Awards $245,000 to Uganda Virus Research Institute (UVRI), Preserving 90 Years of American and Ugandan Scientific Partnership
Entebbe, Uganda – July 22, 2026 - By U.S. Embassy Uganda - The United States has awarded $245,000 through the Ambassador’s Fund for Cultural Preservation (AFCP) to preserve Uganda’s scientific heritage and establish the Uganda Virus Research Institute (UVRI) Museum. The project celebrates nearly 90 years of U.S.-Uganda scientific partnership that has helped protect both Americans and Ugandans from infectious diseases. The museum will preserve and showcase groundbreaking discoveries that have transformed global health, including research on yellow fever, West Nile virus, Zika virus, HIV/AIDS, Ebola, and COVID-19. The initiative reflects America’s enduring commitment to strengthening Uganda’s scientific institutions, preserving shared cultural heritage, and advancing global health security.
The four-year museum project coincides with America’s 250th anniversary in 2026, celebrating shared values of innovation, partnership, and commitment to human progress.
Drug-resistant gonorrhea: Why it matters and what comes next
Newswise - 22-Jul-2026 - by University of California, Los Angeles (UCLA), Health Sciences - Drug-resistant Neisseria gonorrhoeae (the bacterium that causes gonorrhea) has become one of the most urgent antimicrobial resistant threats to public health worldwide. Clinicians expect to be confronted by rising rates of treatment failure in the years to come.
As gonorrhea rates rise and treatment options become more limited, researchers are calling for a more tailored approach that combines new diagnostics, rapid resistance testing, surveillance and additional treatment options for the sexually transmitted disease.
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc.- July 21, 2026 - Gilead - Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP -
- Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV Treatment with Long-Acting Oral Islatravir/Lenacapavir -
- Global Access Momentum Continues for Twice-Yearly Lenacapavir for HIV Prevention, Including Discussions in Latin America -
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums, reflect the company’s person-centered approach to advancing scientific discovery and the importance of partnership to help end the HIV epidemic.
“Progress against the HIV epidemic requires both scientific innovation and enduring partnerships with communities around the world,” said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head, Gilead Sciences. “The data Gilead is presenting at AIDS 2026 reflect our ongoing commitment to advancing HIV prevention, treatment and cure research, with the goal of expanding meaningful choices that can help support the diverse needs, preferences and experiences of people and communities affected by HIV.”
Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026
21 July 2026 (Rio de Janeiro, Brazil) – AIDS 2026 - IAS - International AIDS Society - Studies revealing the real-world impact of disruptions to the US President’s Emergency Plan for AIDS Relief (PEPFAR) and important advances in long-acting HIV prevention and treatment were announced ahead of AIDS 2026, the 26th International AIDS Conference, which will take place in Rio de Janeiro, Brazil, and virtually from 26 to 31 July.
Today’s scientific highlights press conference previewed studies selected from thousands of abstracts that will be presented next week
Convened by IAS – the International AIDS Society – AIDS 2026 will take place at a crucial time in the HIV response. In the face of an unprecedented funding crisis and major cutbacks to HIV programmes, the conference will unite people living with HIV, researchers, policy makers, healthcare professionals, funders, media and communities with the theme Rethink. Rebuild. Rise.
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)-- July 21, 2026 - Gilead - High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials -
- ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment -
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) was effective in adults living with HIV who were virologically suppressed and switched from global guideline-recommended BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) (ISLEND-1) or other standard of care oral daily antiretroviral regimens (ISLEND-2). The safety profile of ISL/LEN was generally similar to the comparator regimens studied in the ISLEND trials, and no new safety concerns were identified. Results of both trials will be presented during late-breaking sessions at AIDS 2026 on Wednesday, July 29 and featured in the AIDS 2026 press program on Tuesday, July 21. These data will form the basis of regulatory submissions.
Trump’s HIV funding cuts having ‘severe and devastating’ impact around the world
July 21, 2026 - By Kat Lay - The Guardian - The President’s Emergency Plan for Aids Relief has saved 26m lives globally, but slashing of funds and dismantling of USAID have forced clinics to shut in dozens of countries
No part of the United States’ anti-HIV programme has escaped unscathed from Donald Trump’s funding cuts, despite pledges from the administration to protect care that saved lives around the world, a new report has found.
Read more...
Zero HIV Stigma Day 2026
July 20, 2026 - By Trent Straube - POZ - This year’s #ZeroHIVStigmaDay theme is “United Towards Zero.” Here’s why that message is more essential than ever.
Tuesday, July 21, marks Zero HIV Stigma Day 2026. It’s a global effort to challenge the stereotypes around HIV and promote the welfare and dignity of people living with HIV, including their ability to access care and maintain adherence to treatment.
Read more...
Why the latest blow to the HIV/AIDS response at the UN should have everyone sounding the alarm
July 19, 2026 - The Conversation - The American and Russian delegations at the United Nations, along with six others, recently voted against the new Political Declaration on AIDS. The United States complained about the inclusion of “divisive” political topics “not related to the fight against AIDS.”
Russia opposed the previous Political Declaration in 2021 on similar grounds, but this represented a seismic change in the American approach to the issue.
As a political scientist studying the diplomacy of HIV/AIDS, I am not surprised by the U.S. but it does alarm me. Even as it reduced foreign assistance and dismantled USAID, the U.S. had maintained a veneer of support for the global AIDS response.
Breaking consensus on the AIDS declaration clearly signals that American political priorities now completely override their participation. This decision can only further politicize debates around the HIV-AIDS response and weaken its reach.
Kaposi Sarcoma Risk in People with HIV Linked to MAVS Gene Variant
19 Jul 2026 Jul 2026 - European Medical Journal - A GENOME-WIDE association study has identified a variant in the MAVS gene associated with Kaposi sarcoma (KS) in people living with HIV, providing the first evidence of inherited susceptibility in children and highlighting a potential biological pathway involved in disease development.
KS is a cancer of the blood vessel lining that is driven by infection with human herpesvirus-8 (HHV-8), with immune deficiency recognised as a key contributing factor. However, because most people with these risk factors do not develop the disease, researchers investigated whether inherited genetic variation may also influence susceptibility.
The finding was observed in both paediatric and adult cohorts living with HIV, supporting further investigation into the role of host genetics in KS susceptibility in high-burden settings.
UNAIDS at the the African Union Extraordinary Session of the Assembly, Accra, Ghana
July 17, 2026 - UNAIDS - African Heads of State and Government will gather in Accra, Ghana, on 21 and 22 July for an Extraordinary Session of the African Union Assembly focused on ending AIDS by 2030, preventing maternal deaths, tackling communicable and non-communicable diseases and strengthening health systems across the continent.
The summit aims to secure a Declaration committing Member States to implement the African Union Roadmap to 2030 and Beyond: Sustaining the AIDS Response, Ensuring Systems Strengthening and Health Security for the Development of Africa, while mobilizing political, programmatic and financial action across priority health challenges.
How HIV Started a Century Before Anyone Noticed
July 16, 2026 - BE SMART - For decades, one man was blamed for bringing AIDS to America. But the “Patient Zero” story was wrong. This is the story of how genetic detective work traced HIV’s true origins—from chimpanzees in Central Africa to a global pandemic—and how science unraveled one of the biggest myths in modern medicine.
UNAIDS at the the African Union Extraordinary Summit in Accra, Ghana, calls for the protection of hard-won AIDS gains and strengthen Africa’s global leadership on health
July 16, 2026 - MEDIA ADVISORY - UNAIDS - UNAIDS spokespeople, including Executive Director Winnie Byanyima, will be available before and during the Summit in Ghana for media interviews
UNAIDS will be at the African Union Extraordinary Summit in Accra, Ghana between 21–22 July 2026. The Summit will be held under the theme, Advancing Justice, Equity and Universal Health Coverage: Ending AIDS, TB, improving maternal health, addressing endemic non-communicable and neglected tropical diseases and conditions in Africa.
At the Summit, UNAIDS will call on African leaders to strengthen Africa’s global leadership on health sovereignty, protect hard-won gains in ending AIDS and accelerate the implementation of the newly-adopted Political Declaration on HIV/AIDSto end AIDS as a public health threat by 2030.
Global Fund Approves Emergency Funding to Protect HIV and TB Services in Venezuela Following Earthquakes
GENEVA – 15 July 2026 - The Global Fund - The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved US$1.77 million in emergency funding to help protect lifesaving HIV and tuberculosis (TB) services in Venezuela following two powerful earthquakes that struck the country on 24 June, killing more than 4,000 people, injuring and displacing thousands more, and disrupting health services.
The Global Fund’s emergency funding will focus on maintaining uninterrupted treatment for people living with HIV and TB while restoring prevention, diagnosis and follow-up services in the affected areas. Implemented through the United Nations Development Programme (UNDP), the funding will also support community outreach, telemedicine and laboratory services during the emergency response.
At-Home, Lab-Quality HIV Tests Awarded $1.3 Million for Development at UMass Amherst
July 15, 2026 - University of Massachusetts Amherst - In early studies, the prototype detected cases of HIV not caught by lab tests
Chang Liu, associate professor in the Riccio College of Engineering at the University of Massachusetts Amherst, wants people to have access to at-home HIV tests sensitive enough for early diagnosis comparable to—or exceeding—lab standards. A new two-year, $1.3 million award from the National Institutes of Health will help him advance his proof-of-concept work toward commercialization.
With 40 years of intervention, AIDS-related mortality has significantly declined to approximately 630,000 deaths per year globally. Despite this progress, 1.3 million new infections occur annually. In the U.S., the “Ending the HIV Epidemic” initiative has made strides, but there are still more than 30,000 new transmissions yearly.
Untold KFF History Volume Three: The Global Media AIDS Initiative
July 15, 2026 - By Drew Altman - KFF - This is the third in my series about the most innovative things we have done over the years at KFF. One big takeaway from these KFF history columns: we keep changing; we don’t always continue what we’ve been doing if the job is done, or it no longer meets a need or an organizational objective. That was the case with one of our most ambitious but relatively short-term efforts—the Global Media AIDS Initiative.
In 2004, in partnership with the United Nations (U.N.) and UNAIDS, we launched the Global Media AIDS Initiative, with regional HIV awareness and prevention media campaigns all over the world.
Press programme for AIDS 2026, the 26th International AIDS Conference
15 July 2026 (Geneva, Switzerland) – IAS - International AIDS Society - The official press conference programme for AIDS 2026, the 26th International AIDS Conference, is detailed below and available online.
Taking place in Rio de Janeiro and virtually, AIDS 2026 is the world’s largest gathering on HIV and AIDS and will bring together leading scientists, policy makers, advocates and communities to shape the future of the global HIV response. The official press programme will include two press conferences: one spotlighting key science featured at the conference and an opening press conference that also includes the annual UNAIDS Global AIDS Update.
All official AIDS 2026 press conferences will be accessible virtually.
All media are required to register for the conference. For more information, please visit the media registration tab on the AIDS 2026 website.
People With HIV Are at Higher Risk for Shingles
July 9, 2026 - By Liz Highleyman - POZ - HIV-positive people are more likely to develop herpes zoster, and do so at younger ages, but vaccination is highly effective.
People living with HIV are about twice as likely as their HIV-negative peers to develop herpes zoster—better known as shingles—but vaccination can close the gap, according to a Canadian study published in the Journal of Infectious Diseases.
Read more...
Tanzania’s Progress in Reducing Mother-to-Child Transmission of HIV
July 14, 2026 - Centers for Disease Control and Prevention (CDC) - At A Glance
To achieve a future free of HIV, it is critical to prevent new HIV infections in infants and ensure mothers living with HIV receive lifelong treatment.
With CDC’s support, Tanzania has made strides in expanding HIV testing, lifelong treatment for pregnant women living with HIV, and early infant diagnosis services.
When Geah was diagnosed with HIV as a young girl, fear and uncertainty shaped her life. Today, she stands in a Dar es Salaam clinic as a trained “Mentor Mother”, supporting more than 200 pregnant women living with HIV and helping them deliver healthy, HIV-free babies. As a mother of two children born without HIV, Geah draws on her own experience to provide guidance, encouragement, and hope.
Her story also reflects Tanzania’s broader progress in reducing mother-to-child transmission (MTCT) of HIV and improving outcomes for mothers and children nationwide.
Changes to Medicaid could have severe consequences for Americans with HIV
July 13, 2026 - By Sarah Boden - Center for Infectious Disease Research and Policy (CIDRAP) - Without Medicaid, Deedee Burris, 53, of Chicago might not be here, or at least he’d likely be a lot less healthy.
Burris was diagnosed with HIV in 1995, and, for much of the past 15 years, he’s been enrolled in Medicaid, a public insurance program that is jointly funded by the federal and state governments. It’s provided Burris with affordable, consistent treatment that turned a fatal condition into a chronic illness.
“It plays a big role. You’re able to get your medication, you’re able to go to your doctor’s visits, your ER [emergency room] visits,” he said.
Medicaid covers 46% of people in the United States living with HIV, making it the largest source of insurance for Americans with this diagnosis. Eligibility is primarily determined by annual income—in most states the cutoff is $22,025 for a single adult. (Other factors include age and disability status.)
But starting January 1, 2027, Medicaid is changing in a big way, and the implications for people with HIV are severe.
Ending AIDS Is at Risk
July 13, 2026 - amfAR, The Foundation for AIDS Research - A new report from UNAIDS details where and how the fight against AIDS is faltering and how the response can rebound
Progress in the HIV response remains tenuous in the face of funding cuts, according to a new UNAIDS report titled United to End AIDS.
In 2025, external support for all facets of international development, including health funding, fell by 23% compared to the previous year. According to UNAIDS, these cuts have severely impacted HIV prevention, testing, attempts to dismantle barriers to services, and community-led services. Between 2024 and 2025, HIV testing programs decreased by 22% in places heavily burdened by the virus. Funding for condoms has been cut by more than 90% in some of these programs. PrEP uptake decreased by 38% between 2024 and 2025 in 62 countries.
AIDS 2026 news coming soon
13 June 2026 - By Amelia Jones - aidsmap - The 26th International AIDS Conference (AIDS 2026) is taking place in Rio de Janeiro, Brazil, and virtually from 26-31 July. aidsmap is an official scientific media partner for the conference.
The theme for AIDS 2026 is ‘Rethink. Rebuild. Rise’.
Read more...
‘I would have died without the care of HIV charity’
June 12, 2026 - By Marcella Whittingdale - BBC - The 26th International AIDS Conference (AIDS 2026) is taking place in Rio de Janeiro, Brazil, and virtually from 26-31 July. aidsmap is an official scientific media partner for the conference.
The theme for AIDS 2026 is ‘Rethink. Rebuild. Rise’.
Read more...
How Canada’s vaccine infrastructure helped guard against infectious disease during the FIFA World Cup
July 12, 2026 - Rose Weeks, Johns Hopkins University - The Conversation - As World Cup fans cheer at the quarterfinals, concerns remain about the health of Norway’s players, several of whom are recovering from what turned out to be mild illness. Other international players had expressed concern earlier about measles in the Americas.
The tournament has highlighted risks related to the volume and fluidity of global travel. From Norway’s elite, handsomely paid squad to the millions of fans congregating at Fan Fests across Canada and the Americas, the quadrennial tournament exposes our interconnected health vulnerabilities.
It’s health security that makes this vibrant bustle possible. As we embrace strangers and shower drinks on neighbours — my 12-year-old son, a Fan Fest regular, particularly appreciates this tradition — Public Health Agency of Canada assesses passengers who appear sick in order to catch exposures to contagious diseases like measles and tuberculosis (TB).
As an American public health scientist working in Canada for the summer, I recently learned about significant preventive health investments, including monitoring for disease risks and major new infrastructure to protect residents from future threats.
Millions who rely on US-funded HIV/AIDS programs face uncertainty as financial cliff looms
June 10, 2026 - By Lauren Kent - CNN - Millions of HIV/AIDS patients, many of them in Africa, face an uncertain future as a financial cliff-edge for US-funded global programs fast approaches. In September, 120 funding awards for HIV/AIDS work carried out by the US Centers for Disease Control are set to expire, with no concrete replacement system in place.
The programs provide services to more than 8.7 million patients worldwide, analysts say, and it’s unclear what will happen to many patient services on the other side of October 1.
Read more...
The Future of the HIV Response: Sustaining Progress in an Era of Political Uncertainty and Scientific Opportunity
July 11, 2026 - By Mitchell Warren - Wiley Online Library - Abstract
The global HIV response is at a pivotal juncture. The field is experiencing a paradox: rapid scientific innovation alongside increasing fragility in financing, political commitment, and implementation systems. Significant progress has been made in expanding access to HIV treatment and prevention, but major gaps in coverage and equity existed previously, that were further exacerbated and destabilized by changes in US government support in January 2025. This commentary examines the implications of this divergence and argues that the future of the HIV response depends less on new biomedical discoveries than on the capacity to deliver existing and emerging options sustainably and with speed, scale and equity. Drawing on recent advances in HIV prevention and treatment, as well as massive disruptions and cuts in both global health programs, including PEPFAR, and biomedical research funding under the new US Presidential Administration, the paper identifies key priorities for the next phase of the response, including strengthening health systems, ensuring equitable access, re-centering community leadership, and securing long-term political and financial commitments. Without decisive action, the gains of the past four decades risk stagnation or, worse, actual reversal; with it, the goal of ending the HIV epidemic may still be achievable.
Public health experts call for renewed attention on HIV/AIDS epidemic
July 10, 2026 - Megan Myscofski - Association of Health Care Journalists (AHCJ) - Why can’t we end the HIV epidemic in the U.S.?
After major developments in treatment for HIV/AIDS in the mid-’90s reduced infection and death rates, media attention shifted away from the epidemic. But experts say they wish attention would return, as federal funding changes and deeper disparities in health care access cause many to go without life-saving treatment.
“If we don’t change the present, I think we’re going to be put into a time machine back to the early ‘90s,” Dr. Demetre Daskalakis, the former director of the CDC National Center for Immunization and Respiratory Diseases, said on a panel at Health Journalism 2026. He resigned from the department last fall and is presently chief medical officer for the Callen-Lorde Community Health Center in New York.
About 4,500 people still die from AIDS every year in the United States. And while highly effective treatments for HIV/AIDS exist, access to them is changing.
Study to examine metabolic complications in adults living with HIV in Nigeria
July 10, 2026 - Vanderbilt Health News - Vanderbilt University Medical Center - Leveraging its expanding non-communicable disease and HIV research portfolio in northern Nigeria, the team also plans to build local capacity in omics analysis.
The Aminu Kano Teaching Hospital (AKTH) and Vanderbilt Institute for Global Health (VIGH) are conducting a research study in northern Nigeria to investigate cardiometabolic disease risk and the metabolic mechanisms behind weight gain in people with HIV, newly treated with antiretroviral therapy (ART).
“Understanding why some individuals experience weight gain beyond a normal ‘return to health’ is critical to enabling earlier, targeted interventions,” said VIGH Director Muktar Aliyu, MBBS, DrPH, professor of Health Policy and Medicine. “Identifying patients at highest risk will enable safer, more personalized care and better long-term outcomes.”
Millions who rely on US-funded HIV/AIDS programs face uncertainty as financial cliff looms
June 10, 2026 - By Lauren Kent - CNN - Millions of HIV/AIDS patients, many of them in Africa, face an uncertain future as a financial cliff-edge for US-funded global programs fast approaches. In September, 120 funding awards for HIV/AIDS work carried out by the US Centers for Disease Control are set to expire, with no concrete replacement system in place.
The programs provide services to more than 8.7 million patients worldwide, analysts say, and it’s unclear what will happen to many patient services on the other side of October 1.
Read more...
Experts publish recommendations on managing low-level but detectable HIV
10 June 2026 - By Zekerie Redzheb - aidsmap - An international panel of scientists reviewed the evidence to construct a framework of recommendations on the management of low-level but detectable HIV. The guidance, published in The Lancet HIV by Dr Tommaso Clemente and colleagues, brings together evidence from a scoping review and expert judgement in order to create a shared point of reference for clinicians.
Read more...
Vivent Health Celebrates 40 Years of Integrated HIV Care
July15, 2026 - By Liz Highleyman - POZ - Launched in Wisconsin, Vivent Health now provides HIV services in six states. CEO Brandon Hill looks back at the transformation.
Vivent Health, formerly known as the AIDS Resource Center of Wisconsin (ARCW), started as a small local health organization with a staff of one. Forty years later, Vivent is a nationally recognized leader in HIV care, prevention and treatment, offering integrated healthcare and social services in Wisconsin, Missouri, Michigan, Illinois, Colorado and Texas.
Read more...
Immune Cells Get Transformed into Fungus-Fighting Nanoparticles
Newswise- 9-Jul-2026, by University of California San Diego - Tiny particles made from the membranes of human immune cells could offer a promising new way to fight fungal infections that are becoming harder to treat. Engineers at the University of California San Diego created antifungal nanoparticles that target Candida albicans, a fungus responsible for oral and vaginal yeast infections as well as life-threatening bloodstream infections. In mice with severe Candida infections, the nanoparticles greatly reduced the amount of fungus in major organs and significantly improved survival.
The research, published in Cell Biomaterials, was led by Liangfang Zhang, professor in the Aiiso Yufeng Li Family Department of Chemical and Nano Engineering at the UC San Diego Jacobs School of Engineering, who also holds the Joan and Irwin Jacobs Chancellor’s Endowed Chair in Innovations for Engineering in Medicine.
From ‘life span’ to ‘health span’ – new guidelines for ageing with HIV in South Africa
9 June 2026 - By Elna Schütz - aidsmap - New clinical guidelines for the care of older people with HIV shift the focus from viral suppression to overall health. As the world’s population of people over 50 years old living with HIV grows, it becomes increasingly important to understand how HIV and geriatric medicine interact.
Read more...
Charlize Theron to be Honored at amfAR’s Second Annual Dallas Benefit Gala
New York, NY, July 8, 2026 - amfAR, The Foundation for AIDS Research - amfAR will recognize philanthropist and Academy Award-winning actor Charlize Theron for her humanitarian work with the organization’s Award of Inspiration at its annual Dallas fundraiser to be held Saturday, October 24, at the home of Kathleen and Scott Kirby. amfAR Dallas is a keystone event for amfAR, raising funds for amfAR’s lifesaving HIV research and efforts to improve global health.
In Sri Lanka, women with HIV or syphilis give birth to healthy babies. Here’s why.
08 July 2026 - By Aanya Wipulasena - Gavi - Sri Lanka’s 2019 elimination of mother-to-child transmission of both viruses is a triumph rooted in proactive healthcare and public trust.
At a glance
When it comes to tracing pregnant women who have dropped out of follow-up care, and are suspected of being HIV or syphilis-positive, there is hardly a place in Sri Lanka’s Colombo district that Public Health Nursing Sister SD Thalagala has not visited.
She recalls spending long hours at a busy bus station for days, hoping to catch sight of a young pregnant woman who hadn’t shown up for her follow-up appointments. When she finally found her, Thalagala managed to convince the mother to return to the clinic. Months later, the mother gave birth to a healthy baby who was free of HIV.
“To date, no mother who started HIV and syphilis treatment at this clinic has transmitted either infection to her baby,” Thalagala said, smiling.
I fear a new HIV and Aids epidemic is coming – and the world won’t care, UN official warns
08 July 2026 - By Chris Stevenson - Independent - At a screening for The Independent’s new documentary ‘Hunted: Kidnapped, blackmailed and tortured for being LGBTQ+,’ UNAIDS official Christine Stegling made clear the danger she sees coming
A UN official has spoken of her fear that aid cuts from the US, UK and other nations could push the world into a new HIV/Aids epidemic – and that people will not care.
Read more...
Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIV
July 7, 2026 - JAMA Network Open - Question
Over the next decade, what will be the costs associated with Medicare beneficiaries aged 65 years or older with HIV, including antiretroviral therapy (ART) costs?
Findings
In this economic evaluation using microsimulation modeling with 111 600 Medicare beneficiaries with HIV at model start, the number of beneficiaries aged 65 years or older receiving care for HIV is projected to increase from 121 890 at the end of 2026 to 193 560 at the end of 2035. Given current ART costs and health care–associated inflation, 10-year cumulative costs to Medicare would be $187.2 billion; however, reducing ART costs by 60% could lower Medicare spending by 38%.
Meaning
These findings suggest that nearly 200 000 people aged 65 years or older with HIV would be enrolled in Medicare by 2035; reducing ART costs while maintaining access to high-quality ART is critical.
The cost of HIV drugs for Medicare is projected to skyrocket by 2035
July 7, 2026 - CIDRAP - Center for Infectious Disease Research & Policy - University of Minnesota - As more people with HIV reach retirement age, the annual cost of antiretroviral therapy (ART) for Medicare for people 65 or older is projected to nearly triple over the next decade, from $6.4 billion in 2026 to $17.8 billion by 2035.
Medicare is the federal health insurance program for older Americans and people with disabilities. The analysis, published today in JAMA Network Open, projects that 63% of the cumulative cost to Medicare for older beneficiaries living with HIV will be to pay for ART, which is the lifelong treatment that suppresses the virus to non-detectable levels. Without these antiviral medications, HIV goes from a chronic to a fatal condition.
The study based its cost projections on current ART prescribing patterns, healthcare-associated inflation, and data showing that more people with HIV are living into their 70s and 80s because of ART.
Chuck Solomon: Coming of Age - 1986 AIDS Documentary by Marc Huestis and Wendy Dallas
July 6, 2026 - By Marc Huestis and Wendy Dallas - Vimeo - Chuck Solomon: Coming of Age is one of the first generation AIDS documentaries. Made in 1986, it was a loving tribute to theatre director Chuck Solomon, who had recently been diagnosed with AIDS as well as losing his brother and lover to the disease. Much of it takes place at his 40th birthday, a gathering of over 200 people who were an integral part of his life, and who as a community could as Chuck said “could celebrate even in the face of horrible things, instead of retreating behind closed doors and drawn shades”. A film by Marc Huestis and Wendy Dallas, the award winning documentary showed in 25 International Film Festivals, including the prestigious Berlin Film Festival, aired on England’s Channel 4, Spains TV 3, CBC in Canada, as well as multiple PBS stations in the US.
Why gender matters in the fight against HIV, tuberculosis and malaria
July 6, 2026 - Cordaid International - Health is not gender-neutral. Gender norms, stigma, unequal power relations, legal barriers and economic insecurity all shape whether people can access prevention, testing, treatment and care.
To introduce this topic, Cordaid has developed a general infographic on how gender and health intersect. It shows how gender can shape people’s health risks, their access to services, the quality of care they receive, and their role in health decision-making.
Alongside the infographic, this background paper takes a closer look at one specific area: how gender influences the fight against HIV, tuberculosis and malaria — and how the Global Fund to Fight AIDS, Tuberculosis and Malaria responds. It shows how adolescent girls and young women face heightened HIV risks, how stigma and social expectations can delay TB diagnosis and treatment for both women and men, and why malaria prevention often fails to reach pregnant women and other vulnerable groups.
SAMRC and Ospedale San Raffaele Launch Phase I Trial of Long-Acting HIV Prevention Antibody
6, Jul 2026 - South African Medical Research Council | SAMRC - Phase I adult study will assess the safety and pharmacokinetics of long-acting prevention antibody (ePGT121v1-LS) to support future studies aimed at preventing HIV transmission in children
The South African Medical Research Council (SAMRC), in partnership with the Unit of Viral Evolution and Transmission at IRCCS Ospedale San Raffaele Hospital – Milan (Italy), is pleased to announce the initiation of a Phase I clinical trial, PedMab1-Ex, evaluating the broadly neutralising antibody (bNAb) ePGT121v1-LS in healthy adult participants.
The SAMRC leads this research, with Dr Terusha Chetty, Deputy Director at the SAMRC HIV and other Infectious Diseases Clinical Research Unit (HIDRU), serving as the national Principal Investigator (PI) and Dr Gabriella Scarlatti, Group Leader at IRCCS Ospedale San Raffaele, as the co-PI. The team has previously collaborated on the successful European and Developing Countries Clinical Trials Partnership that funded the PedMAb1 phase 1 clinical trial in infants, which assessed the safety and pharmacokinetics of two bNAbs in infants born to women living with HIV.
Scripps Research scientists train the immune system to make antibodies against numerous HIV strains
LA JOLLA, CA - July 6, 2026 - Scripps Research - Preclinical findings mark progress toward a long-sought vaccine capable of broad protection against HIV.
HIV is globally so diverse, consisting of hundreds of thousands of different strains, that antibodies capable of blocking one strain may not recognize another. This strain variability has been one of the greatest barriers to developing a vaccine that can provide broad protection against the virus. But rather than hoping the immune system stumbles onto the right antibodies, scientists at Scripps Research and collaborating institutions designed a series of immunizations to guide a subset of precursor B cells—white blood cells that can mature into cells that release antibodies—through a step-by-step training process termed germline-targeting sequential immunization. Each successive shot was engineered to activate the appropriate B cells and then nudge them closer to producing broadly neutralizing antibodies (bnAbs): rare antibodies that are able to recognize and block many different HIV strains.
New virus catalogue reveals which pathogens pose the greatest threat
July 6, 2026 - Mark Woolhouse, University of Edinburgh - The Conversation - In a typical year, scientists discover two or three viruses that have never been seen in people before. The number fluctuates, but the trend has been fairly steady since the 1960s.
Most of these viruses attract little attention, and my colleagues and I have often had to search through old medical papers to find any mention of them. Some viruses disappear entirely and are all but forgotten. At the other extreme, the discovery of HIV-1 in 1983 and Sars-CoV-2 in 2020 presaged the Aids and COVID pandemics, respectively. Both have killed tens of millions.
The next time a scientist finds an unusual or unknown virus in a patient – probably in the next few months – how will they know whether it could lead to a public health emergency on the same scale as Aids or COVID? My team at the University of Edinburgh has been using the lessons of virus history to help answer this question.
Making It Matter
July 6, 2026 - By Michael Aksten - POZ - I was diagnosed with HIV in 2009. Shortly after, my condition progressed rapidly to AIDS, with a CD4 count of 10. At that point, I was told in no uncertain terms that I would not live to see much of a future.
What followed was a decade-long fight for survival.
Read more...
SAMRC Vice-President appointed as Nelson Mandela University Medical School’s first Honorary Professor
6, Jul 2026 - South African Medical Research Council | SAMRC - Nelson Mandela University is honoured to announce the appointment of Professor Liesl Zühlke as the Honorary Professor linked to the medical school. Prof Zühlke, a paediatric cardiologist, is the Vice-President: Extramural Research and Internal Portfolio at the South African Medical Research Council (SAMRC).
Professor Zühlke is the first recipient of an honorary professorship linked to the Medical School since it was established in 2021.
Welcoming the appointment, Mandela University Vice-Chancellor Professor Sibongile Muthwa said: “The appointment of Professor Zühlke as an Honorary Professor marks a significant milestone in the development of our Medical School and the Department of Public Health. As a globally recognised clinician-scientist, her contributions to public health research, capacity building and health equity have had a profound impact in South Africa and beyond. Her appointment reflects our commitment to academic excellence, innovative health research and partnerships that strengthen healthcare systems.”
Pakistan hit by new mass HIV outbreak among children
July 6, 2026 - By Samaan Lateef - The Telegraph - At least 78 children contracted the virus at a government-run hospital accused of re-using contaminated syringes
Pakistan has launched an investigation after dozens of children were infected with HIV at a government-run hospital, amid allegations that contaminated syringes were reused.
Read more...
How Leaders are Responding to HIV/AIDS in Belize
July 5, 2026 - By Hayden Randolph - The Borgen Project - As of 2024, Belize has an HIV prevalence rate of 1.6%. The rate is one of the highest of any Latin American country. Discrimination against people living with the disease hinders efforts to minimize the transmission of HIV/AIDS in Belize.
The History of HIV/AIDS in Belize
AIDS first showed up in Belize in 1986 and is one of the leading causes of death for Belizeans. The disease disproportionately affects gay and bisexual men in the country with people between 15-24 years of age being the largest portion of new infection. Only half of the estimated 3,700 people infected with HIV/AIDS in Belize are receiving treatment.
‘The Fight of our Lives’ – David Levithan and Gabriel Duckels’ generation-spanning history of the AIDS epidemic
July 4, 2026 - By Brian Bromberger - Bay Area Reporter - This year marks the 45th anniversary since the Centers for Disease Control (CDC) and Prevention published a clinical report in its June 5 “Morbidity and Mortality Weekly Report” about five young gay men in Los Angeles who had developed a rare and deadly pneumocystis pneumonia (PCP), with three of the men dead by the time it was printed. Then on July 3, 1981, the New York Times published an article on a rare skin cancer called Kaposi’s sarcoma affecting 41 gay men in New York and Los Angeles, eight of whom had already died.
Read more...
Ending HIV in the Asia-Pacific
July 3, 2026 - By Kianna Phosouvanh-Sythong - The Borgen Project - With an estimated 320,000 new HIV infections expected annually by 2030, accelerating HIV programs in the Asia-Pacific is crucial to ending the epidemic before it worsens.
Asia and the Pacific account for 23% of new HIV infections globally each year. In 2024, about 6.9 million people living with HIV resided in the Asia-Pacific alone. Progress remains uneven in many countries, with some even seeing an increase in HIV incidence. Without proper procedures and resources, HIV will continue to rise in the Asia-Pacific.
An AIDS-free generation is within reach, but not guaranteed
July 3, 2026 - By Anurita Bains, UNICEF Associate Director for HIV and Health - Al Jazeera - For more than four decades, the global AIDS response has been powered by grief, rage, courage and determination. Families buried loved ones long before their time. Communities confronted discrimination and built networks of care when the silence was deafening. Scientific breakthroughs and community-driven innovation transformed HIV from a near-certain death sentence into a chronic, manageable condition. The result is one of the greatest public health achievements of the past half century. That success is now under threat.
Read more...
U.S. Aid Withdrawal for HIV ‘Devastating’
BRATISLAVA, Jul 2 2026 (IPS) - By Ed Holt - Inter Press Service (IPS) - A U.S. decision to cut off funding for HIV projects in South Africa has been condemned amid warnings it could be “catastrophic” for efforts to control the disease in the country.
At the start of last year, the White House had announced massive cuts to U.S. foreign aid, including to South Africa, significantly impacting some HIV projects in the country.
But last month (June 2026), U.S. officials confirmed plans to begin a drawdown of what remaining financial support it was providing through the President’s Emergency Plan for AIDS Relief (PEPFAR), saying the money was no longer needed given South Africa’s wealth but also seemingly linking the move to the government’s failure to meet specific U.S. political demands.
‘Opt-out’ HIV testing risks confusion about consent, legal experts warn
2 July 2026 - UNSW SYDNEY - As opt-out HIV testing expands into new healthcare settings, doctors and patients need clarity on its potential legal consequences. Here’s why.
Under a public health policy aimed at eliminating HIV transmission, you might now be tested for HIV while checking common conditions such as cholesterol levels and kidney function.
Experts at UNSW say this is a shift away from conventional testing that could reduce stigma and increase diagnosis rates, but one that risks overlooking a crucial factor: the patient's informed consent.
Scientia Associate Professor David Carter, a medico-legal expert from UNSW Law & Justice, says the move towards opt-out HIV testing could have severe legal implications for patients and doctors.
Planning for the future at UNAIDS’ 58th Board meeting
GENEVA, 2 July 2026 - UNAIDS - Just one week after Member States adopted a new Political Declaration on HIV/AIDS at the United Nations General Assembly in New York, the 58th Programme Coordinating Board (PCB) took the next step in shaping how the Joint United Nations Programme on HIV/AIDS (UNAIDS) will evolve to help deliver those commitments.
Building on the renewed global political commitment to end AIDS as a public health threat by 2030, Board members reaffirmed the need for a strong, coordinated global HIV response while advancing discussions on how the Joint Programme should accompany the global response in a changing financial and global health landscape.
He thought it was just a rash. He nearly died of AIDS.
July 2, 2026 - By Charles Trepany - USA TODAY - At first, Cody Pharis didn't think much of the rash on his legs.
Same goes for his swollen lymph nodes a year prior. Both ended up going away and seemed like minor issues. Maybe he had contact dermatitis, he thought. Or a vitamin deficiency. Either way, he was fine, right?
Read more...
UNAIDS supports efforts to protect the continuity of the HIV response during the emergency in Venezuela
CARACAS/PANAMA CITY, 1 July 2026 - UNAIDS - UNAIDS mourns the tragic loss of life and expresses solidarity with the people and communities affected by the devastating earthquakes that struck Venezuela on 24 June. UNAIDS reaffirms its commitment to supporting efforts to ensure the continuity of HIV-related services during the emergency.
“The disruption of health services and population displacement caused by the disaster have created significant challenges for people living with HIV and other vulnerable populations,” said Luisa Cabal, UNAIDS Regional Director for Latin America and the Caribbean. “UNAIDS is working alongside national authorities, United Nations agencies, community organizations and development partners to help ensure support and continued access to HIV treatment, care and information.”
Medical Frailty and Medicaid Work Requirements: Challenges for People with HIV
July 1, 2026 - Authors: Lindsey Dawson and Jennifer Tolbert - KFF - On June 1, 2026, the Centers for Medicare and Medicaid Services (CMS) issued an interim final rule providing states with guidance for implementing Medicaid “community engagement” or Medicaid work requirements as part of the 2025 federal budget reconciliation law. The law requires states to condition Medicaid eligibility for enrollees with coverage through the Affordable Care Act (ACA) expansion or under certain waivers on meeting these requirements or qualifying for an exclusion, including one related to being “medically frail or otherwise” having “a special medical need.” In defining medical frailty, the rule introduces a two-part test, requiring an enrollee to both have a qualifying condition and demonstrate that the condition impairs their ability to fulfill the community engagement requirement, differing from stakeholders’ expectations. Early on, and as with Nebraska’s early implementation, states believed they would be able to exclude people based on presence of a condition alone and several states planned to exclude all people with HIV.
Scripps Research scientists awarded $2M to advance global disease surveillance
LA JOLLA, CA - July 01, 2026 - Scripps Research - Two Gates Foundation grants will expand wastewater surveillance and AI-driven disease monitoring to support faster public health responses worldwide.
Detecting infectious disease threats early and responding quickly can dramatically alter the course of an infectious outbreak. Technologies such as wastewater surveillance are transforming how public health officials identify emerging pathogens, monitor community transmission and direct resources where they’re needed most. Scripps Research has been at the forefront of this effort, developing computational and laboratory tools that have helped make wastewater disease tracking a reality for global health.
Now, with two new grants from the Gates Foundation totaling $2 million, Scripps Research scientists will further expand these capabilities—developing more comprehensive wastewater surveillance technologies while building artificial intelligence systems to integrate diverse data and improve outbreak prediction. Both awards are part of the Modjadji Initiative, an effort to build affordable, scalable pathogen surveillance systems, particularly for low- and middle-income countries (LMICs).
Older Adults with HIV Face Barriers to Staying Housed. That Could Hurt Efforts to Slow HIV’s Spread.
July 1, 2026 - By Madison Alvarado - San Francisco Public Press - First generation of long-term HIV survivors highlights challenges in city’s aging services, calling for more support.
Jerry Cuffey, 74, believes he shouldn’t have been alive to speak to the Board of Supervisors.
Infected with HIV 38 years ago, the long-term survivor has a higher chance of developing diabetes and kidney disease.
“I was supposed to not be here,” he told the board on June 16, pleading with them to set aside more money to support the 11,500 people over 50 years old with HIV in San Francisco. “Help me keep going.”
Read more...
Broadway Cares Awards $3 Million in Grants to 265 Organizations
July 1, 2026 - By Andrew Gans - Playbill - The record-breaking sum expands access to healthcare, housing, and other support nationwide.
Broadway Cares awarded a record $3,007,500 last month to 265 organizations, providing health care, housing, emergency assistance, and other support to those facing illness and hardship across the country.
Read more...
For more HIV and AIDS News visit…
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
Back to Top
HIV/AIDS News
|
